Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 95

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Triple negative breast cancer+4

Recruiting

Study Comparing Sacituzumab Govitecan Alone and with Pembrolizumab for Patients with Low-Risk, Triple-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Colorectal cancer+3

Recruiting

Study on Tislelizumab for Cancer Patients with Molecular Residual Disease After Standard Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Institut Gustave Roussy

Hormone-dependent prostate cancer

Recruiting

Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Unicancer

Neoplasm

Recruiting

Study of Zenocutuzumab for Patients with Solid Tumors with NRG1 Fusion

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zenocutuzumab
  • Sponsor:Partner Therapeutics Inc.

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib and Obinutuzumab vs. Venetoclax and Obinutuzumab for Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Adenocarcinoma gastric+1

Recruiting

Study on the Effects of Rilvegostomig and Drug Combination for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azd0901
  • Sponsor:AstraZeneca AB

Glioblastoma

Recruiting

Study on Lomustine and Temozolomide for Newly Diagnosed Glioblastoma Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Region Oestergoetland

Glioblastoma

Recruiting

Study on Glioblastoma Treatment with Olaptesed Pegol and Radiation, with Bevacizumab or Pembrolizumab, for Patients with Unmethylated MGMT Promoter

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:TME Pharma AG

Breast cancer

Recruiting

Study of Tuvusertib and Fulvestrant for Advanced Breast Cancer Resistant to CDK4/6 and Aromatase Inhibitors in Hormone Receptor-Positive, HER2-Negative Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Institut Paoli-Calmettes

Neoplasm

Recruiting

Study on the Safety and Tolerability of D3S-001 Alone or with Drug Combination in Adults with Advanced Solid Tumors with KRAS p.G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:D3 Bio (Wuxi) Co. Ltd.

Diffuse large B-cell lymphoma

Recruiting

Study on Golcadomide for Patients with Relapsed or Refractory Aggressive Large B-Cell Lymphoma at High Risk of Relapse After CAR T-Cell Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:LYSARC

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.